CINtec PLUS Cytology provides a triage solution that informs better risk stratification for HPV-positive screening results3.

 

The next evolution in Cervical Cancer screening for healthcare professionals.

The next evolution in Cervical Cancer screening for healthcare professionals.

Not every HPV-positive woman will develop Cervical Cancer, so triage can determine who is most at risk and will benefit from more immediate follow-up, and who is at low risk and can be given more time to clear the infection on her own. CINtec PLUS is a triage cytology test that helps stratify disease risk immediately, giving clinicians confidence when selecting the appropriate management for women at every level of risk.

Detect changes at the cellular level

Detect changes at a the cellular level

CINtec PLUS Cytology has dual-biomarker technology for more definitive results.

It’s not enough to know that a patient is positive for HPV, but whether HPV is causing changes at the cellular level. CINtec PLUS Cytology is available in Australia for patients with positive high risk HPV results.
It is a test that uses dual-biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results.

The co-expression of these two biomarkers is a strong indicator that an HPV infection is undergoing oncogenic transformation.

CINtec PLUS Cytology can help you identify patients needing immediate care and reassure those who can safely wait.

Resources

CINtec PLUS Cytology can help you identify patients needing immediate care and reassure those who can safely wait.

International Journey of Cancer Article: p16/ki‐67 dual stain triage of individuals positive for HPV to detect cervical precancerous lesions.

 
Click here to read and
download the journal article
 
Download the CINtec PLUS
Guide for HCPs
 

Resources

 

International Journey of Cancer Article: p16/ki‐67 dual stain triage of individuals positive for HPV to detect cervical precancerous lesions

Click here to read and 
download the journal article

 
Download the CINtec PLUS
Guide for HCPs

Ready to request a test?

 

Arrange a test with
Sonic Healthcare+

Arrange a test with
VCS Pathology+

+Disclaimer:  By clicking these links you'll leave a Roche website. Roche is not responsible for content published on non-Roche websites. 

 
 

 

Would you like to know more? Leave your details and our team will be in touch.

*For HPV16/18+ use as additional information in conjunction with the physician’s assessment of patient screening history, other risk factors, and professional guidelines to guide patient

management. hr = high risk

References:
1. Walmers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
2. CINtec PLUS Cytology [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.; 2020. Data from the IMPACT trial.
3. Wright TC, et al. Clinical validation of p16/Ki-67 dual-stained cytology triage of HPV-positive women: Results from the IMPACT trial. IJC. 2022;150(3):461-471.

 

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. 
ALWAYS READ THE LABEL AND FOLLOW THE DIRECTIONS FOR USE.

 

COBAS and CINTEC are trademarks of Roche.
©2025 Roche.

Published by: Roche Diagnostics Australia Pty Limited.

2 Julius Ave, North Ryde NSW 2113.
Phone: +61 2 9860 2222
ABN 29 003 001 205

MC-AU-03752

 

Roche Diagnostics Australia